BETHESDA Md., April 25, 2013 /PRNewswire/ -- TNI BioTech, Inc. (OTC PINK: TNIB) is pleased to announce that they have named Terry Lierman from the Summit Global Ventures as a strategic advisor to the company. In this capacity, Mr. Lierman will provide strategic and tactical direction to improve operational productivity for the company's growth plans.
"Terry Lierman is renowned on capitol hill for both his political skills and his passionate support of improved healthcare and funding for medical research. He has proven over the last four decades that he has the ability to combine his entrepreneurial and political talents," said Noreen Griffin, chief executive officer and director of TNI BioTech, Inc. "His executive experience in the field of healthcare, especially as it applies to cancer and HIV/AIDS, will be invaluable over the coming year." Terry Lierman has served in leadership positions on the staff of the U.S. Senate, and is the founder of a number of companies and non-profit organizations that advance healthcare advocacy.
Commenting on his appointment, Mr. Lierman said: "TNI BioTech has the key ingredients of a successful company in the field of immunology: a highly motivated workforce and a passionate commitment to improving the lives of patients. I am looking forward to working with the TNI BioTech team."
About Terry Lierman
Terry Lierman began his career in the health field at the National Institutes of Health (NIH), where he assisted in budget and policy development, grants, and contracts. He then moved to the U.S. Senate Committee on Appropriations, where he was the staff director of both the labor Health and Human Services (HHS) appropriations committee and subcommittee.
Mr. Lierman founded several companies and organizations, including the Children's Research Institute at the Children's Hospital National Medical Center, the National Coalition for Cancer Research, the National Organization on Fetal Alcohol Syndrome (NOFAS), and the Pancreatic Cancer Action Network (PANCAN). He was the chair of the Maryland Democratic Party and served as the chief of staff to the House of Representatives majority leader and democratic whip congressman, Steny H. Hoyer.
Mr. Lierman is presently on venture capital boards, president of Energy One, and the founder of Summit Global Ventures. He now chairs the Institute of Human Virology and serves on the boards of the GVN (Global Virus Network), as well as the Council for a Livable World and Peace PAC.
About TNI BioTech, Inc.
TNI BioTech, Inc. is a biotech company with the goal of benefitting patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system, using a patented immunotherapy.
Their products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer, chronic infections such as HIV/AIDS, and autoimmune diseases and, such as Crohn's disease, other types of inflammatory bowel disease, and multiple sclerosis.
TNI BioTech's most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone (LDN), which both work by triggering opioid receptors on immune cells, leading to an activation and expansion of various cells of the immune system.
Their proprietary technology, therapies, and patents are planned to treat a wide range of cancers. Their most advanced clinical programs involve immunotherapy that works by augmenting the number and functions of both T cells and natural killer (NK) cells in patients with deficient immune responses associated with advanced cancer or HIV/AIDS and by rebalancing the immune responses in patients with autoimmune diseases, including Crohn's disease and multiple sclerosis (MS).
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
See http://www.tnibiotech.com for more information.
Contact: Global Investment Media
SOURCE TNI BioTech, Inc.